GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1RAs, a class of glucose-lowering medication used to treat diabetes and obesity, may offer antidepressant effects. UF ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

For instance, the review showed that GLP-1 drugs may have promising outcomes for people with dementia or other neurological disorders. “There is also evidence for mechanisms involving a reduction of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists ... levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of GLP-1 receptor agonist ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Glucagon-like peptide-1 (GLP-1) receptor agonists ... levels and aiding weight loss due to their unique pharmacological mechanisms. A research team from the School of Public Health, in the ...

For instance, the review showed that GLP-1 drugs may have promising outcomes for people with dementia or other neurological disorders. “There is also evidence for mechanisms involving a ...